HALO
Halozyme Therapeutics, Inc.
$77.54
+1.72 (+2.27%)
At close · Jul 16
Market Cap
$9.20B
Shares
118,613,000
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Darren Snellgrove | Chief Financial Officer | Appointed | 2026-04-30 |
Key facts
CIK
1159036
CUSIP
40637H109
13F (30d)
78 filings
73 filers
Visit website
Investor relations